Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKLB1028 Combined With 7+3 Chemotherapy in Newly Diagnosed FLT3+ AML
NCT05445154Phase 2Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruserontinib in acute myeloid leukemia (AML), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Aug 2021; status: recruiting.
02
Drugs
ruserontinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05445154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445154.